FHFabio José Haddad

Fabio José Haddad

*This is an algorithmically generated author record based on publicly available information.

Fabio José Haddad has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cryptococcosis with an endobronchial tumor-like growth in an immunocompetent patient

    by Felipe Marques da Costa, Bruno Lima Moreira, Milena Tenório Cerezoli, Christina Shiang, Fábio José Haddad

    A 60-year-old woman nonsmoker presented with a 3-month history of progressive dyspnea, cough, sputum production, and weight loss. She worked as a librarian in an old building and reported no prior medical history of note.


  • Open Access

    Evaluation of Magnetic Resonance Imaging of the Chest at a Cancer Center

    by Juliana Cristina Duarte Braga, Diogo Fábio Dias Teixeira, Bruno Hochhegger, Pablo Rydz, Jefferson Luiz Gross, Fabio Jose Haddad, Carine Rosa Naue, Marcos Duarte Guimarães

    Objective: In the present article, we will describe the indications for chest MRI in patients diagnosed with malignancy and its relevant role in distinguishing benign from malignant lesions and in detecting metastases. Materials and methods: Single-center, retrospective, analytical imaging and chart-review study of all patients with a diagnosis of cancer who underwent chest MRI at the Imaging Department of A.C. Camargo Cancer Center from January 2014 through December 2016. Information was collected through an electronic questionnaire and exported to a Microsoft Excel spreadsheet. Data were then processed in Action Stat 3 software. Descriptive analysis was conducted with conventional measures of central tendency (mean, median, mode) and dispersion (range, variance, standard deviation, and coefficient of variation), as well as calculation of absolute and relative frequencies. Results: The leading indication for chest MRI was post-treatment follow-up. Chest MRI was most often requested by the Departments of Thoracic Surgery and Clinical Oncology. In most cases, the results of chest MRI led to maintenance of the current treatment plan rather than a change in management. Conclusion: Magnetic resonance imaging has several applications in evaluation of the chest, and can be used by various specialties and subspecialties. In the present study, post-treatment follow-up and maintenance of current therapy were the most common indication and management, respectively. For several decades, technical limitations discouraged the use of magnetic resonance imaging (MRI) for the diagnosis of diseases of the chest cavity. However, recent technological advances have made it possible to overcome these challenges, and MRI is currently recognized for offering numerous advantages in chest imaging, such as high resolution, soft tissue contrast and the possibility of functional assessment of the lung and thoracic masses. In this study, the main indications for chest MRI in patients diagnosed with malignancy and its relevant role in distinguishing benign and malignant lesions and in the detection of metastases are described, aiming to identify the main indications and findings of chest MRI and its impact on clinical management of an oncology center. This is a single-center, retrospective, analytical study carried out by reviewing the medical records of all patients diagnosed with cancer undergoing chest MRI at the Department of Images of the AC Camargo Cancer Center from January 2014 to December 2016. The main indication for chest MRI was post-treatment follow-up. Chest MRI was most frequently requested by the Departments of Thoracic Surgery and Clinical Oncology. In most cases, chest MRI results led to maintenance of the current treatment plan rather than a change in management. Magnetic resonance imaging has several applications in the assessment of the chest and can be used by different specialties and subspecialties. In the present study, it was concluded that chest MRI was most frequently used for post-treatment follow-up, and the most common response to MRI findings was to continue current treatment.

  • Open Access

    The role of the surgeon in treating patients with lung cancer. An updating article

    by Paulo Manuel Pêgo-Fernandes, Fabio José Haddad, Carlos Jogi Imaeda, Marcel Sandrini

    Lung cancer is a type of neoplasia with one of the highest incidences worldwide and is the largest cause of mortality due to cancer in the world today. It is classified according to its histological and biological characteristics, which will determine its treatment and prognosis. Non-small cell lung cancer accounts for 85% of the cases, and these are the cases that surgeons mostly deal with. Small cell lung cancer accounts for the remaining 15%. Surgery is the main method for treating early stage lung cancer, and lobectomy is the preferred procedure for treating primary lung cancer, while sublobar resection is an alternative for patients with poor reserve or with very small tumors. Surgeons need to be trained to use the resources and techniques available for lung resection, including less invasive approaches such as video-assisted thoracoscopic surgery (VATS) and robotic-assisted thoracoscopic surgery (RATS), and need to be familiar with new oncological approaches, including curative, adjuvant or palliative treatments for patients with lung cancer.


  • Open Access

    Bronchial carcinoid tumors: second primary neoplasms and outcomes of surgical treatment

    by Jefferson Luiz Gross, Marcel Adalid Tapia Vega, Guilherme Strambi Frenhi, Silvio Melo Torres, Antonio Hugo José Froes Marques Campos, Clovis Antonio Lopes Pinto, Felipe D’aLmeida Costa, Fabio José Haddad

    Objective: To analyze determinants of prognosis in patients with bronchial carcinoid tumors treated surgically and the potential concomitance of such tumors with second primary neoplasms. Methods: This was a retrospective analysis of 51 bronchial carcinoid tumors treated surgically between 2007 and 2016. Disease-free survival (DFS) was calculated by the Kaplan-Meier method, and determinants of prognosis were evaluated. Primary neoplasms that were concomitant with the bronchial carcinoid tumors were identified by reviewing patient charts. Results: The median age was 51.2 years, 58.8% of the patients were female, and 52.9% were asymptomatic. The most common histology was typical carcinoid (in 80.4%). Five-year DFS was 89.8%. Ki-67 expression was determined in 27 patients, and five-year DFS was better among the patients in whom Ki-67 expression was ≤ 5% than among those in whom it was > 5% (100% vs. 47.6%; p = 0.01). Concomitant primary neoplasms were observed in 14 (27.4%) of the 51 cases. Among the concomitant primary neoplasms that were malignant, the most common was lung adenocarcinoma, which was observed in 3 cases. Concomitant primary neoplasms were more common in patients who were asymptomatic and in those with small tumors. Conclusions: Surgical resection is the mainstay treatment of bronchopulmonary carcinoid tumors and confers a good prognosis. Bronchial carcinoid tumors are likely to be accompanied by second primary neoplasms.